Verley, a French biotech firm, has achieved a regulatory milestone as the U.S. Food and Drug Administration (FDA) issued a “No Questions Letter” for two of its precision-fermented dairy proteins, approving their safety for food use.
This FDA clearance allows Verley to enter the U.S. market in 2026, marking the first time precision-fermented dairy proteins have received such approval, and positions the company for future global expansion.
Precision fermentation uses microorganisms to produce dairy proteins without animal farming, offering a sustainable alternative to traditional dairy production. Verley’s cleared proteins include FermWhey™ Native, a whey protein rich in β-lactoglobulin, and FermWhey™ MicroStab, formulated to enhance stability in complex food products like ready-to-drink beverages.
This regulatory approval follows Verley’s earlier achievement of GRAS (Generally Recognized As Safe) status for its precision-fermented whey protein, which further supports its entry into conventional markets. The company’s leadership highlights rapid progress since its foundation, emphasizing the promising potential of precision fermentation to reshape protein sourcing sustainably.
In the broader context, consumer demand is rising for alternative protein sources that reduce environmental impact, and precision fermentation is emerging as a key innovation in this area. As the global food industry seeks solutions to climate challenges and animal welfare concerns, Proteins made by precision fermentation offer a scalable, eco-friendly option.
Verley is actively engaging with regulatory bodies outside the U.S. to extend market access and is collaborating with food and beverage manufacturers worldwide to integrate these sustainable proteins into diverse products.
Related topics
